

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

NK-92

RRID:CVCL_2142

Type: Cell Line

Proper Citation

RRID:CVCL_2142

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2142

Proper Citation: RRID:CVCL_2142

Description: Cell line NK-92 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Natural killer cell lymphoblastic leukemia/lymphoma

Defining Citation: [PMID:8152260](#), [PMID:9118301](#), [PMID:9573023](#), [PMID:10365666](#), [PMID:10803505](#), [PMID:11454312](#), [PMID:12850795](#), [PMID:16827800](#), [PMID:18424763](#), [PMID:19194464](#), [PMID:20454443](#), [PMID:21052088](#), [PMID:21570725](#), [PMID:25586472](#), [PMID:26559813](#), [PMID:30054012](#), [PMID:31126350](#), [PMID:31160637](#), [PMID:34349345](#), [PMID:36610812](#)

Comments: Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NK-92

Synonyms: NK92, Natural Killer-92, NK-92.05, Neukoplast, aNK

Cross References: BTO:BTO_0003287, CLO:CLO_0008177, EFO:EFO_0022517, AddexBio:C0003026/NA, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2407, BCRC:60414, BioSample:SAMN03471836, CCRID:4201HUM-CCTCC00052, CCTCC:GDC0052, Cell_Model_Passport:SIDM01143, Cosmic:1534874, Cosmic:1542071, Cosmic:2025326, Cosmic:2390215, Cosmic:2785204, DSMZ:ACC-488, DSMZCellDive:ACC-488, GEO:GSM472001, IPD-IMGT/HLA:13674, Lonza:1093, Wikidata:Q17149636

ID: CVCL_2142

Record Creation Time: 20220427T221344+0000

Record Last Update: 20260725T235722+0000

Ratings and Alerts

No rating or validation information has been found for NK-92.

Warning: Discontinued: ATCC; PTA-6670

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line. **Warning:** Discontinued: BCRC; 60414

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 412 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou Y, et al. (2025) Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e11573.

Gao T, et al. (2025) Molecular basis of $\alpha 2$ integrin activation by talin unveils subunit-specific mechanisms of integrin signaling. Cell reports, 44(5), 115607.

Phung SK, et al. (2025) A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer. Cancer immunology research, 13(2), 258.

Stransky N, et al. (2025) Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells. iScience, 28(5), 112523.

Cai HM, et al. (2025) DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis. Cell reports, 44(9), 116237.

Sasaki N, et al. (2025) RNA sensing induced by chromosome missegregation augments anti-tumor immunity. Molecular cell, 85(4), 770.

B?dzi?ska A, et al. (2025) The puzzling regulation of the interferon signaling system by the p53 tumor suppressor protein. Cellular and molecular life sciences : CMLS, 82(1), 233.

Nikolic I, et al. (2025) Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. Cancer cell.

Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. Cancer research, 85(13), 2448.

Ning K, et al. (2025) Non-destructive in situ monitoring of structural changes of 3D tumor spheroids during the formation, migration, and fusion process. eLife, 13.

Decalf J, et al. (2025) Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations. EBioMedicine, 118, 105822.

Maskalenko NA, et al. (2025) The Fc γ RIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing. Cancer immunology research, 13(3), 417.

Hai Y, et al. (2025) An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma. *Journal of experimental & clinical cancer research* : CR, 44(1), 306.

Liu Y, et al. (2025) ITGA5-expressing tumor cells interact with Schwann cells to drive nerve growth factor-mediated immunosuppression of NK cells. *Molecular therapy : the journal of the American Society of Gene Therapy*.

Liu Z, et al. (2025) A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. *Cell*, 188(11), 3081.

Polten R, et al. (2025) Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblasts. *Oncoimmunology*, 14(1), 2556714.

Sætersmoen M, et al. (2025) Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor. *Med (New York, N.Y.)*, 6(2), 100521.

Kok N, et al. (2025) CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells. *iScience*, 28(6), 112548.

Peng Y, et al. (2024) Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapy. *International journal of cancer*, 154(7), 1285.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.